Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Treating Breakthrough Bleeds with NovoSeven® RT

Actor portrayal

Treating Breakthrough Bleeds with NovoSeven® RT

Actor portrayal

Treating Breakthrough Bleeds with NovoSeven® RT

Actor portrayal


Acute bleeds require urgent action1:

Help patients beat breakthrough bleeds2

House icon

"When he became more active, we knew where to turn for a fast home treatment for his breakthrough bleeds.”3

Having an on-demand agent on hand helps keep patients prepared to act quickly.

For CHAwI or CHBwI.

Actor portrayal.

NovoSeven® RT is a first choice for treating breakthrough bleeding for hemophilia A with inhibitors (CHAwI) patients on emicizumab.2

MASAC logo

MASAC recommends rFVIIa to treat acute bleeds in patients with congenital hemophilia A with inhibitors taking emicizumab prophylaxis2

Use of FEIBA® (anti-inhibitor coagulant complex) for breakthrough bleed treatment for patients on emicizumab should be avoided if possible, and rFVIIa should be the first option used to treat acute bleeding events as the use in combination with emicizumab does not alter the rFVIIa safety profile.2

Duration of FEIBA® therapy should also be minimized, as prolonged use for >24 hours with doses above 100 IU/kg/day may be associated with thrombosis and TMA.2

Justin lives with hemophilia A with inhibitors

Justin lives with hemophilia A with inhibitors

NovoSeven® RT was the only recombinant factor used for breakthrough bleeds in patients with inhibitors in the Hemlibra® pivotal clinical trials4,a 

During the HAVEN studies, in patients receiving Hemlibra® prophylaxis for breakthrough bleeds in pivotal clinical trials4:

 

• 180 bleeds were treated with NovoSeven® RT only in HAVEN14,a

• No serious AEs and no cases of TMA or TE demonstrated in 3 pivotal trials with use of NovoSeven® RT alone4,a

• Two cases of TMA occurred in patients receiving FEIBA® and NovoSeven® RT. Simultaneous use of NovoSeven® RT and FEIBA® should be avoided5

No new or unexpected safety concerns related to concomitant use of NovoSeven® RT and emicizumab were identified in the HAVEN1, HAVEN2, and HAVEN4 clinical trials4,a

Justin lives with hemophilia A with inhibitors

Justin lives with
hemophilia A
with inhibitors

aThe analysis included bleeding episodes in the HAVEN1, HAVEN2, and HAVEN4 clinical trials for which patients with CHAwI on emicizumab prophylaxis (at the labeled dose) used rFVIIa. Initial individual dosing with rFVIIa, dosing intervals, and cumulative dosing were evaluated. All AEs reported in each of the 3 trials, including available narratives, were assessed. The cut-off dates for data presented were for HAVEN1 (primary analysis) September 2017; HAVEN2 (interim analysis) October 2017; and HAVEN4 (primary analysis) December 2017.4

AE=adverse event; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors; rFVIIa=recombinant factor VIIa; TE=thrombotic event; TMA=thrombotic microangiopathy.


Real-world results reinforce:
administering NovoSeven® RT early makes a difference6

Congenital hemophilia A and B with inhibitors trial data showed NovoSeven® RT to be 93% effective at resolving bleeds.7,b

In the post hoc analysis of SMART-7™, a large, prospective, postmarketing study of patients with CHwI, early treatment (≤1 hr) with NovoSeven® RT effectively resolved bleeds6,c

96.5% pie chart

All bleeds
N=307

96.2% pie chart

Joint bleeds
N=176

97.3% pie chart

Muscle bleeds
N=72

The post hoc analysis of real-world study SMART-7™ aligns with NovoSeven® RT clinical trial results for hemophilia patients with inhibitors experiencing mild-to moderate bleeding episodes.6,7

 

bData from an international, multicenter, randomized, double-blind, active-controlled, confirmatory phase 3 trial of patients with hemophilia A with inhibitors (n = 66) or hemophilia B with inhibitors (n = 6). Primarily carried out in the home setting, all bleeds were treated, and each bleeding episode was randomized (3:2) to infuse either 1 to 3 doses of vatreptacog alfa (340 bleeding episodes; 80 mcg/kg) or 1 to 3 doses of NovoSeven® RT (227 bleeding episodes; 90 mcg/kg) when bleed symptoms were recognized, preferably within 2 hours of onset. The primary efficacy endpoint indicated that effective bleed control was defined as no additional hemostatic medication (other than the original medication) given within 12 hours after the initial dose.7

cSMART-7™ was a prospective, observational, single-arm, open-label study conducted over the course of 5 years (patients remained in the study for maximum 2 years or until 25 exposure days of on-demand rFVIIa), including 51 patients with CHAwI or CHBwI, that monitored decreased therapeutic response treated with the room temperature–stable formulation of rFVIIa and the development of neutralizing antibodies toward FVII. Patients evaluated the status of bleeding episodes after each treatment as “bleed stopped,” “bleed slowed,” or “no change/worsened.” Based on these evaluations, treatment was described as “effective,” “partially effective,” or “ineffective,” respectively. The post-hoc data set included 482 bleeding episodes reported by 45 patients treated with rFVIIa. Patients included in the post-hoc subgroup analysis required the hemostatic response to treatment with rFVIIa monotherapy, by time to first treatment and in different age cohorts was assessed for bleeds satisfying the following four criteria: (1) valid efficacy assessment, (2) no missing time for bleed start, (3) no missing time for any dose administration, and (4) valid time to first treatment. The small number of patients in each of the age cohorts assessed and the differences between the time-to-treatment subgroup sizes are limitations of the study that should be taken into account. It is also possible that the rFVIIa monotherapy group could have largely comprised patients with milder disease or bleeding, as these patients may be more likely to receive a single effective treatment compared with patients with more severe bleeding. In addition, the results need to be considered in light of the fact that this was a post hoc analysis.6


NovoSeven® RT effectively controls joint bleeds—fast.8

Hemostasis was  achieved with a median of 2 doses.8,d

Clock displaying 2 hours

Quick readministration

NovoSeven® RT can be readministered as quickly as every 2 hours compared with 6 to 12 hours for FEIBA®9,10

Medication icon

Median 2 doses

A median of 2 doses helped control joint bleeds in as little as 5 hours for patients with CHwI8,d

Person standing next to an up arrow

Maximum activity

NovoSeven® RT achieved maximum activity within 5-10 minutes of infusion11,e,f

dData from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with and without an inhibitor. Patients were given NovoSeven® RT at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if a patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable relief of pain/tenderness or decrease in bleeding.8

eData from a randomized, double-blind trial of healthy subjects (N=22) who received 1 intravenous bolus injection each of NovoSeven® RT and NovoSeven®. Both bolus injections were 90 mcg/kg and occurred 2 to 3 weeks apart at consecutive visits. While the comparison is not shown for FVIIa, activity for NovoSeven® RT was the bioequivalent range of that for NovoSeven® during this period.11

fFVIIa activity IU/mL.11

Two people standing, having their arm, nose, and knee highlighted

 

Teach patients the signs and symptoms of internal bleeds

This educational resource may be able to help your patients quickly identify bleeds when and where they happen. Use this tool to help your patients identify breakthrough bleeds which may require treament on-the-go.

Try the Bleed ID Tool

Ordering NovoSeven® RT

Learn how you can order NovoSeven® RT for your patients with rare bleeding disorders

 

See how to order

Actor portrayal

When would you treat a breakthrough bleed?

Learn more about assessing breakthrough bleeds

Questions about how NovoSeven® RT can help your patients?

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References

1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.

2. MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed December 19, 2022. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors

3. Data on file. Novo Nordisk Inc.; Plainsboro, NJ.

4. Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost.  2019;17(9):1470-1477.

5. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818 and appendix.

6. Demartis F, Batorava A, Chambost H, et al. Real-world early treatment with room temperature–stable recombinant factor VIIa in hemophilia A/B and inhibitors: SMART-7™ post hoc analyses. TH Open. 2017;1(2):e130-e138.

7. Lentz SR, Ehrenforth S, Abdul Karim FA, et al; Adept™2 Investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12(8):1244-1253.

8. Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798. doi:10.1046/j.1365-2516.1998.00209.x

9. NovoSeven RT. Package insert. Novo Nordisk Inc; 2020.

10. FEIBA. Package insert. Baxter Healthcare Corporation; 2023.

11. Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23NSVN00011 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials